<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>5(27)</volume><submitter>Kargbo RB</submitter><pubmed_abstract>A second-generation kilogram-scale synthesis of the psychedelic tryptamine psilocybin has been developed. The synthesis was designed to address several challenges first encountered with the scale-up of previously described literature procedures, which were not optimized for providing consistent yield and purity of products, atom economy, or being run in pilot plant-scale reactors. These challenges were addressed and circumvented with the design of the second-generation route, which featured an optimized cGMP large-scale Speeter-Anthony tryptamine synthesis to the intermediate psilocin with improved in-process control and impurity removal over the three steps. Psilocin was subsequently phosphorylated directly with phosphorous oxychloride for the first time, avoiding a tedious and poor atom </pubmed_abstract><journal>ACS omega</journal><pagination>16959-16966</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7364850</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin.</pubmed_title><pmcid>PMC7364850</pmcid><pubmed_authors>Dagger RE</pubmed_authors><pubmed_authors>Tarpley G</pubmed_authors><pubmed_authors>Cozzi NV</pubmed_authors><pubmed_authors>Kaylo K</pubmed_authors><pubmed_authors>Patterson T</pubmed_authors><pubmed_authors>Meisenheimer P</pubmed_authors><pubmed_authors>Sable J</pubmed_authors><pubmed_authors>Walker A</pubmed_authors><pubmed_authors>Kargbo RB</pubmed_authors><pubmed_authors>Sherwood A</pubmed_authors><pubmed_authors>O'Hern K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin.</name><description>A second-generation kilogram-scale synthesis of the psychedelic tryptamine psilocybin has been developed. The synthesis was designed to address several challenges first encountered with the scale-up of previously described literature procedures, which were not optimized for providing consistent yield and purity of products, atom economy, or being run in pilot plant-scale reactors. These challenges were addressed and circumvented with the design of the second-generation route, which featured an optimized cGMP large-scale Speeter-Anthony tryptamine synthesis to the intermediate psilocin with improved in-process control and impurity removal over the three steps. Psilocin was subsequently phosphorylated directly with phosphorous oxychloride for the first time, avoiding a tedious and poor atom </description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jul</publication><modification>2025-04-21T17:07:03.663Z</modification><creation>2025-04-21T17:07:03.663Z</creation></dates><accession>S-EPMC7364850</accession><cross_references><pubmed>32685866</pubmed><doi>10.1021/acsomega.0c02387</doi></cross_references></HashMap>